

Alejandro Gutierrez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2514311/publications.pdf>

Version: 2024-02-01

72
papers

6,331
citations

109321

35
h-index

128289

60
g-index

74
all docs

74
docs citations

74
times ranked

11120
citing authors

#	ARTICLE	IF	CITATIONS
1	An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. <i>Science</i> , 2014, 346, 1373-1377.	12.6	665
2	SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. <i>Nature</i> , 2011, 471, 104-109.	27.8	558
3	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 647-650.	1.4	414
4	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	27.8	355
5	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 364-370.	21.4	333
6	An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. <i>Leukemia</i> , 2018, 32, 1970-1983.	7.2	282
7	Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 209-221.	16.8	262
8	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
9	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	9.4	201
10	Liquid Chromatography/Electron Capture Atmospheric Pressure Chemical Ionization/Mass Spectrometry: % Analysis of Pentafluorobenzyl Derivatives of Biomolecules and Drugs in the Attomole Range. <i>Analytical Chemistry</i> , 2000, 72, 3007-3013.	6.5	197
11	Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 644-655.	8.2	180
12	The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 4169-4173.	1.4	162
13	METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. <i>Molecular Cell</i> , 2021, 81, 3323-3338.e14.	9.7	153
14	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. <i>Cancer Cell</i> , 2010, 18, 353-366.	16.8	141
15	Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. <i>Blood</i> , 2012, 120, 3764-3773.	1.4	132
16	c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. <i>Blood</i> , 2014, 123, 1040-1050.	1.4	129
17	Cyclin C is a haploinsufficient tumour suppressor. <i>Nature Cell Biology</i> , 2014, 16, 1080-1091.	10.3	124
18	TYK2 "STAT1" BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	9.4	122

#	ARTICLE	IF	CITATIONS
19	Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. <i>British Journal of Haematology</i> , 2007, 138, 169-175.	2.5	115
20	Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 2845-2851.	1.4	112
21	The TAL1 complex targets the <i>FBXW7</i> tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2013, 210, 1545-1557.	8.5	107
22	NOTCH and PI3K-AKT Pathways Intertwined. <i>Cancer Cell</i> , 2007, 12, 411-413.	16.8	106
23	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 1595-1603.	8.5	104
24	Absence of Biallelic <i>TCRβ</i> Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3816-3823.	1.6	93
25	Alu elements mediate <i>MYB</i> gene tandem duplication in human T-ALL. <i>Journal of Experimental Medicine</i> , 2007, 204, 3059-3066.	8.5	85
26	Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors. <i>Haematologica</i> , 2014, 99, 94-102.	3.5	84
27	Liquid chromatography–mass spectrometry (LC–MS) of steroid hormone metabolites and its applications. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 546-555.	2.5	78
28	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. <i>Cancer Cell</i> , 2019, 35, 664-676.e7.	16.8	70
29	Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1735-1745.	1.4	61
30	Aberrant AKT activation drives well-differentiated liposarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16386-16391.	7.1	50
31	Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1819-1827.	7.2	49
32	TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2017, 7, 1336-1353.	9.4	48
33	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	7.2	48
34	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the β -secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000539.	1.2	47
35	Shared acquired genomic changes in zebrafish and human T-ALL. <i>Oncogene</i> , 2011, 30, 4289-4296.	5.9	42
36	Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. <i>Genes and Development</i> , 2017, 31, 1456-1468.	5.9	41

#	ARTICLE	IF	CITATIONS
37	Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. <i>Cancer Discovery</i> , 2020, 10, 1690-1705.	9.4	38
38	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	8.5	37
39	A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1395-1402.	1.5	34
40	Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. <i>Molecular and Cellular Biology</i> , 2009, 29, 5911-5922.	2.3	33
41	NOTCH1 Signaling Promotes Human T-Cell Acute Lymphoblastic Leukemia Initiating Cell Regeneration in Supportive Niches. <i>PLoS ONE</i> , 2012, 7, e39725.	2.5	31
42	Acute myeloid/T-cell lymphoblastic leukaemia (<scp>AMTL</scp>): a distinct category of acute leukaemias with common pathogenesis in need of improved therapy. <i>British Journal of Haematology</i> , 2018, 180, 919-924.	2.5	29
43	Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05 and 11. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28719.	1.5	26
44	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 1929-1945.	8.5	22
45	Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 335-369.	1.6	19
46	Loss of function <i>p53</i> mutations do not accelerate the onset of <i>myc</i> -induced T-cell acute lymphoblastic leukaemia in the zebrafish. <i>British Journal of Haematology</i> , 2014, 166, 84-90.	2.5	16
47	Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2019, 14, e0221288.	2.5	16
48	Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	12
49	PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis. <i>Leukemia</i> , 2021, 35, 679-690.	7.2	11
50	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	7.2	6
51	An X-linked tumor suppressor in T-ALL. <i>Blood</i> , 2015, 125, 3-4.	1.4	4
52	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. <i>American Journal of Hematology</i> , 2010, 85, 135-137.	4.1	3
53	Supramolecular assembly of GSK3 β as a cellular response to amino acid starvation. <i>Molecular Cell</i> , 2022, 82, 2858-2870.e8.	9.7	3
54	Leukemia Propagating Cells Akt Up. <i>Cancer Cell</i> , 2014, 25, 263-265.	16.8	2

#	ARTICLE	IF	CITATIONS
55	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. <i>Blood</i> , 2012, 120, 3558-3558.	1.4	2
56	An Off-the-Shelf, Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies. <i>Blood</i> , 2017, 130, 844-844.	1.4	2
57	Thymocyte transformation enhanced. <i>Nature Medicine</i> , 2014, 20, 1096-1097.	30.7	1
58	Pathobiology of Acute Lymphoblastic Leukemia. , 2018, , 1005-1019.e11.		1
59	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	1.4	1
60	Molecular Targeted Therapies in T-Cell Acute Lymphoblastic Leukemia. , 2010, , 19-30.		1
61	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. <i>Journal of Cell Biology</i> , 2011, 194, i4-i4.	5.2	1
62	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1470-1470.	1.4	1
63	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. , 2019, 231, .		1
64	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukemias. <i>Blood</i> , 2006, 108, 1405-1405.	1.4	0
65	Large Scale Copy Number Variation Upregulates the Expression of MYB in Human T-ALL. <i>Blood</i> , 2006, 108, 1408-1408.	1.4	0
66	Pten Inactivating Mutations Promote Loss of MYC Oncogene Addiction in a Conditional Zebrafish Model of T-ALL. <i>Blood</i> , 2009, 114, 3977-3977.	1.4	0
67	Cell and molecular biology of human leukaemias. , 2010, , 4214-4221.		0
68	Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL. , 2014, , .		0
69	Abstract IA8: A new class of drugs active in T-ALL is revealed in a zebrafish screen. , 2014, , .		0
70	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. <i>Blood</i> , 2018, 132, 889-889.	1.4	0
71	Inducible Phase Separation of GSK3 β As a Mechanism for Asparaginase Resistance in Acute Leukemias. <i>Blood</i> , 2019, 134, 169-169.	1.4	0
72	SOD2 Promotes Acute Leukemia Adaptation to Amino Acid Starvation Through the N-Degron Pathway. <i>Klinische Padiatrie</i> , 2022, , .	0.6	0